Al­ny­lam's R&D up­date in­cludes 3 halts, Alzheimer's time­line and an­oth­er NASH

Al­ny­lam Phar­ma­ceu­ti­cals tout­ed its high prob­a­bil­i­ty of suc­cess in bring­ing as­sets from Phase I to Phase III — about 62% com­pared to an in­dus­try av­er­age of 5% to 10% — in an R&D up­date Thurs­day.

But, even the RNAi drug de­vel­op­er with five med­i­cines now un­der its wings will come out with the scis­sors and scrap stud­ies it finds lack­ing, as the Boston-area biotech out­lined in an in­vestor pre­sen­ta­tion. That in­cludes cem­disir­an for kid­ney dis­ease IgA nephropa­thy, an ear­ly-stage drug for gout and lumasir­an for re­cur­rent re­nal stones.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN